Canadian group benefits insurers are recalibrating how they price and structure drug plans as employer coverage of glucagon-like peptide-1 drugs continues to broaden, according to new survey data from the International Foundation of Employee Benefit Plans, which has tracked GLP-1 coverage in Canada since February 2024. The shift is not incremental: total claims paid by Canadian insurers for weight-loss drugs doubled in a single year, from roughly $38 million in 2023 to approximately $77 million in 2024, and the structural features of how most employers are covering these drugs mean the cost sits inside core plan renewals rather than a ring-fenced product insurers can price and cap independently.
The IFEBP survey found 51% of employers now cover GLP-1 drugs for diabetes only, down from 66% just two years ago, while coverage for both diabetes and weight loss has more than doubled over the same period from 17% to 37%. For group insurers, that shift changes the underwriting profile of drug plans: weight-loss GLP-1 use tends to be broader-based and longer-duration than diabetes-specific prescribing, and insurers are now pricing renewals against a moving target rather than a stable, well-understood drug class.
Most employers that do cover weight-loss GLP-1s route the benefit through a standard prescription drug plan at 85%, rather than a separate weight management vendor solution at 12% or a supplemental rider at 4%. That routing means the cost sits inside the core drug plan renewal rather than a ring-fenced product insurers can price and cap independently - a structural feature that amplifies the repricing challenge as utilisation broadens.
Carey Wooton, associate vice president of education at IFEBP, said the dynamic is squarely a cost-versus-demand problem. "Coverage of GLP-1 drugs for weight loss in Canada continues to rise. Employers remain tasked with meeting employee demand while mitigating rising costs," she said.
Health Canada's April 2026 approval of the first generic semaglutide - making Canada the first G7 country to reach that milestone - is the single biggest variable insurers are now pricing around, and its effect on plan costs is more complex than a simple unit-price reduction.
Under the pan-Canadian Pharmaceutical Alliance's tiered framework, first-generic pricing runs 75% to 85% of brand cost, falling toward 35% once three or more generics are listed. Falling per-claim pricing from generics will likely expand the share of plan sponsors willing to add weight-loss coverage - but rising utilisation means insurers cannot assume falling drug prices translate into falling plan costs at renewal, a pattern seen with past generic transitions in other high-cost drug classes where volume growth offset unit-price declines.
Frédéric Leblanc, pharmacist at iA Financial who works directly on drug management strategy for group insurance clients, gave the generic transition its proper long-term framing: "Every time a generic comes to market, there is a break on expenses for a few years. But new medications are always coming, so it's a cycle and we have to realize that we are always funding more medications."
Sun Life has said that where a plan sponsor already lists a brand-name drug such as Ozempic or Wegovy, the generic equivalent will generally be added to the formulary automatically once available, while members who prefer to stay on the brand product will pay the price difference themselves.
Among employers not yet covering weight-loss GLP-1s, 73% of those declining coverage do so through a carve-out exclusion from their medical or drug plan, according to the IFEBP survey. That figure reflects employer choices rather than confirmed insurer direction, but it aligns with carve-outs' broader use as a standard risk-management lever while a drug class is still repricing.
Prior authorisation is a related lever already documented at specific carriers. Desjardins Insurance has said it will require physician-submitted documentation before approving claims for generic equivalents of Ozempic, giving underwriters a control point that did not exist when these drugs were prescribed almost exclusively for diabetes. Only about 30% of iA Financial plan members currently have any obesity or weight management coverage, a figure insurers expect to move as pricing shifts. Manulife, Sun Life and Canada Life have all indicated they are actively monitoring the GLP-1 landscape and preparing plan sponsors for changes, treating this as a live pricing and product design issue rather than a settled cost line.
For group benefits insurers, GLP-1s are becoming a live product-design problem rather than a one-time cost shock. Insurers that build out formulary and utilisation management for this drug class now are better positioned to compete on renewal pricing than those still treating it as a diabetes-only line, though how large that advantage proves to be will depend on how quickly the rest of the market catches up.
Brokers advising plan sponsors will need to weigh carve-outs, prior authorisation and vendor point solutions against straightforward inclusion in the core drug benefit - a decision that will look different depending on the plan sponsor's risk appetite, workforce demographics and how aggressively their insurer is already repricing the exposure.
